Stifel analyst Thomas Stephan tells investors that the firm’s iDose survey was “solid” and reinforces the firm’s continued long-term bullish stance on the product and on Glaukos (GKOS)’ stock. The recent selloff in shares “appears overdone,” says the analyst, who is adding Glaukos to the Stifel Select List and advises investors use the recent pullback to “opportunistically buy key value drivers of the stock at an attractive valuation.” The firm keeps a Buy rating and $115 price target on Glaukos shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos Receives Buy Rating from Analyst Ryan Zimmerman Due to Strong Growth and Promising Product Potential
- Needham medtech & diagnostics analysts hold analyst/industry conference call
- Glaukos Highlights Innovation in Recent Investor Presentation
- Glaukos Corp. Reports Record Growth Amid Challenges
- Glaukos price target raised to $118 from $117 at BTIG